The extracellular matrix (ECM) is composed of several types of proteins, which interact and form dynamic networks. These components can modulate cell behaviour and actively influence the growth and differentiation of tissues. ECM is also important in several pathological processes, such as cancer invasion and metastasis, by creating favourable microenvironments. Proteolysis in neoplastic tissues is mediated by proteinases, whose regulation involves complex interactions between neoplastic cells and non-neoplastic stromal cells. In this review, we discuss aspects of proteinase expression and tumor behaviour in humans and dogs. Different classes of proteases are summarized, with special emphasis being placed on molecules that have been shown to correlate with prognosis, reinforcing the need for a better understanding of the regulation of this microenvironment and its influences in tumor progression and metastasis, which should significantly aid the development of improved prognosis and treatment.
Introduction
It is known that the extracellular matrix (ECM) not only determines tissue architecture but also stores growth factors, cytokines, proteases, hormones and other bioactive molecules, which interact with the cell surface and affect cell migration, adhesion, proliferation, differentiation and apoptosis. 1 The composition of the ECM is variable, consisting of several types of collagen, non-collagenous proteins, elastic fibers and proteoglycans, which interact and form dynamic networks. 2 Thus, ECM components can modulate cell behaviour and actively influence the growth and differentiation of tissues.
Renewal of the ECM is an important part of physiological processes such as development, tissue remodeling, cell growth and differentiation. There is increasing evidence that the ECM is also important in several pathological processes, such as cancer invasion and metastasis, by creating favourable microenvironments. 3, 4 Extracellular proteolysis in neoplastic tissues is mediated by proteinases, whose regulation involves complex interactions between neoplastic cells and non-neoplastic stromal cells. 5 -7 Several studies are currently under development in an attempt to better understand the tumoral metastatic process in humans and dogs. Nevertheless, in veterinary medicine, oncologic pathologists and researchers are still at a very early stage in identifying how the activity and function of proteases and stroma are related to canine cancer malignancy. 8 Proteolytic enzymes involved in the process of invasion and metastasis include urokinase plasminogen activator (uPA) complex, 9 -13 matrix metalloproteinases (MMPs) 2,14 -16 and cathepsins 17 (Fig. 1) . Some of these molecular components involved in matrix degradation have clinical value as prognostic markers in oncology, and inhibition of extracellular proteolysis is recognized as a valid approach to cancer therapy. Research in this field has been an important tool for the clinical management of cancer patients. 13 Despite the recent explosion of information regarding protease-related molecules, questions about how they may influence tumor tissue architecture and how alterations in their expression may be responsible for cancer progression from a single malignant cell to a lethal metastatic disease need further investigation for each species. Furthermore, these enzymes exhibit considerable flexibility in their interactions depending on the tumor, type of analysis and studied species, resulting in complex expression patterns of proteases.
In this review, we discuss aspects of proteinase expression and tumour behaviour in humans and dogs. Different classes of proteases are summarized, with special emphasis being placed on molecules that have been shown to correlate with prognosis.
Gelatinases -MMP-2 and MMP-9
The first evidence of the involvement of MMPs in cancer came from studies in animal models. During experimental transplantation of tumor cells in mice, it was found that benign tumour cells with increased MMP expression acquired malignant features. Reduction in the expression or activity of MMPs, on the other hand, reverted that aggressive tumor behaviour. 18 Itoh et al. 19 found that tumor cells injected into MMP-2 and MMP-9 deficient mice showed lower ability to colonize the lungs. Similarly, increased expression of MMP-1 and MMP-7 leads to proliferative diseases, increasing susceptibility to cancer. 20 The main role attributed to MMPs in cancer is in promoting invasion and metastasis; more specifically, MMPs may open a path in the ECM through which tumor cells could move to colonize distant tissues. 21 It is known that MMPs can also induce proliferation, cell adhesion and migration, not only by ECM degradation but also through release of growth factors and fragments of ECM proteins. 22 Tumor cells stimulate adjacent stromal cells to synthesize MMP in a paracrine manner, via interleukins, interferons, extracellular MMP inducer (EMMPRIN) and growth factors. 20 MMPs secreted by stromal cells may also be recruited to the membrane of tumor cells. 23 MMP-2 and MMP-9 have demonstrated a unique ability to degrade basement membranes, because the main constituent of these membranes is type IV collagen. 24 Overall, metalloproteinases are overexpressed in malignant neoplasms due to changes in gene transcription, conferring a poor prognosis for a variety of cancers. 25, 26 35 showed that higher gelatinase levels in cancer cells were correlated with local and regional recurrence in breast cancer patients. Since then, the prognostic value of MMP-2 and MMP-9 detection has become controversial, regardless of the technique: some studies have reported no prognostic significance for these proteins, 36,37 whereas others have associated high MMP expression levels with worse prognoses. 38, 39 Moreover, stromal cell expression of gelatinases was considered a prognostic marker for human neoplasms. 40 -45 Miya et al. 46 reported that malignant canine tumors do not necessarily present higher gelatinase activity, and suggested that, instead, benign neoplasms with inflammation could have increased the activity of gelatinases. Localization of MMP-2 and MMP-9 was evaluated in canine neoplastic tissues such as mammary carcinomas, mast cell tumors and oronasal tumors. 46 -50 Type IV collagenases were detected in normal myoepithelial cells, fibroblasts and malignant epithelial cells from normal and neoplastic canine mammary tissues. 47 Hirayama et al. 51 described MMP-2 and MMP-9 immunopositivity in mammary tumors and detected higher levels of MMP-9 in malignant lesions in comparison to benign ones. In agreement with these results, Nowak et al. 52 observed positive correlation between MMP-9 expression and proliferative activity measured through Ki67 expression. High MMP-9 expression in neoplastic mammary cells was considered an independent predictor for survival in human breast cancer, 38 as well as in stromal cells, whereas MMP-2 levels did not differ significantly. 38,53 -56 MMP-2 expression seems to be a more important predictor in canine mammary tumors, because its expression in carcinomas is higher than that in normal mammary glands, 57, 58 and also higher than that in tumor-associated fibroblasts. 59 Kawai et al. 60 analyzed the active forms of metalloproteinases in canine mammary neoplasms by zymography, and found higher MMP-2 and MMP-9 gelatinolytic activities in carcinomas than in adenomas. Dogs with malignant mammary tumors also showed higher levels of these enzymes in blood serum. 46, 61 The prognostic value of metalloproteinase expression was also investigated in mast cell tumors.
46,62 -64 The levels of MMP-2 and MMP-9, measured using zymography, were positively correlated with histopathological grades. 62, 64 Immunohistochemical detection of MMP-9 was also confirmed as a prognostic indicator in this type of neoplasm. 49, 62 In canine osteosarcomas, both MMP-2 and MMP-9 activities were increased compared with normal bone. 62, 65 Furthermore, a strong correlation was found between MMP expression and histopathological grading as well as other important clinical parameters used in the formulation of a prognosis. 62 Osteosarcoma cell lines were also positive for these enzymes in zymographic and immunocytochemical assays. 66 Neoplastic cells from canine hemangiosarcomas expressed MMP-2, whereas MMP-9 was restricted to the inflammatory infiltrate. 67 Meningiomas were also investigated for gelatinase expression.
Despite immunohistochemical positivity for these MMPs in meningiomas, none of the proteins were correlated with malignant morphological patterns in dogs. 68 These results oppose those obtained from human tumors, in which collagenases are highly expressed in intracranial meningiomas. 69 MMP activity in the cerebrospinal fluid of dogs with central nervous system neoplasms was increased, but it was suggested that this might be due to leukocyte infiltration in the tumour. 70 Immunocytochemical and quatitative real timepolymerase chain reaction (qRT-PCR) analyses revealed higher expression of MMP-2 and MMP-9 in canine leukaemia samples than in normal peripheral blood. In addition, the levels of MMP-9 in chronic lymphocytic leukaemias were higher than in acute leukaemia. 71 Active forms of the collagenases were quantified in dogs with lymphoma, both in tumoral tissue and blood. 72, 73 Gentilini et al. 72 found correlation between MMP-9 and vascular endothelial growth factor (VEGF) expressions, suggesting that the protease is involved in tumoral angiogenesis. Patients in the study showed higher levels of active MMP-9 and VEGF than the control group.
Newman et al. 74 showed correlation between MMP2 expression and canine lymphoma histological grades, as well as correlation with the immunophenotype. In that report, MMP-2 expression was considered a marker for worse prognosis. However, MMP-2 expression was not considered an important marker for canine lymphoma by others. 73 Results from studies of MMP-2 expression in human lymphomas are also contradictory. Some demonstrate MMP-2 expression by neoplastic lymphocytes, 75 whereas others focus on MMP-2 production by fibroblasts and macrophage tumors. 76 
Urokinase plasminogen activator (uPA)
Plasminogen, the zymogen form of plasmin, is mainly produced by the liver. It is a constituent of plasma, and is also present in interstitial fluid. 77 Conversion to its active form, plasmin, occurs locally through proteolysis by two types of serine-protease plasminogen activators: the urokinase-type (uPA) and tissue-type (tPA). 78 
-81
The primary role of tPA is formation of plasmin for thrombolysis, whereas uPA is more frequently associated with degradation and repair of the basement membrane and other extracellular proteins. 82 -84 uPA is secreted in its inactive form, pro-uPA. 77 When bound to its specific receptor (uPA-R), uPA converts plasminogen to plasmin, a protease capable of degrading pericellular fibrin, fibronectin and laminin. 85 -90 Plasmin also activates other proteases, such as gelatinases (MMP-2 and MMP-9), 91 collagenases (MMP-1) 92 and stromelysins (MMP-3). 93 Furthermore, uPA shows receptor-independent activities, which include proteolysis of plasmin and MMPs and chemotaxis of vascular smooth muscle cells, 94 and is mitogenic for melanoma cell. 95 Owing to these features, involvement of this protease in cancer invasion and metastasis have been studied. 13, 96, 97 In neoplastic tissues, stromal components can express uPA, as well as other proteases. 2, 98 The production of uPA has been described in tumor-associated fibroblasts, macrophages, neutrophils and also cancer cells. 99 -104 The first studies focused on the synthesis of uPA by tumor cells, 77, 105 but this approach changed when immunoreactivity for uPA, as well as mRNA production, were found to be restricted to stromal cells (fibroblasts and endothelial cells) in human uterine cancer. 106, 107 The immunohistochemical localization of uPA in human breast carcinomas has been reported by several authors. 108 -112 Other studies consider stromal and macrophage positivity as prognostic factors for mammary neoplasms. 112, 113 In addition, high uPA mRNA and protein levels were correlated with shorter disease-free intervals and survival and, consequently, worse prognosis. 114 -117 These findings were independent of other predictors such as histological grading, tumor size and hormone receptor status. 12, 118 Few veterinary studies have compared uPA expression with the progression of tumors. 119, 120 Canine mammary tumors showed positive immunostaining for uPA in neoplastic epithelial and myoepithelial cells, in addition to stromal fibroblasts and macrophages. Santos et al. 119 found that increased expression of uPA was negatively correlated with disease-free intervals and survival. Similarly, Golshahi et al. 120 demonstrated association between stromal expression of this serine-protease and histopathological grade of canine mammary neoplasms.
Cathepsins
Cathepsins comprehend a diverse lysosomal protease family composed of various catalytic types. Among them, aspartic cathepsins (cathepsins D and E) and cysteine cathepsins (cathepsins B, C, F, H, K, L, O, S, V, X and W) stand out. 121 -123 Although these enzymes are stored in lysosomes and related to intracellular protein turnover, 124 they can be released in the cytosol, directed to the cytoplasmic membrane or secreted into the extracellular space. 125 -128 It is also suggested that cathepsins initiate proteolytic cascades of serine-proteases and MMP. 129, 130 Furthermore, cathepsins may facilitate tumoral invasion, a malignancy hallmark, through an alternative pathway that involves the proteolysis of E-cadherin, resulting in a loss of E-cadherin function in several neoplasms. 131 -134 These features allow ECM remodeling, stimulate proliferation and apoptosis and activate angiogenesis, promoting invasion and metastasis in cancer. 135, 136 Participation of aspartic-proteases in oncology, namely cathepsins D and E, is especially related to the capacity of cathepsin D in cleaving laminin, fibronectin and proteoglycans. 137 Cathepsin E is present in lymphocytes, microglia and Langerhans cells. 138 Westley and Rochefort 139 showed that cathepsin D expression could be induced in mammary cancer cells by estradiol. Subsequently, other reports showed its mitogenic effect in mammary cancer cell lines 140 and catalytic effect through degradation of the ECM. 141 It is known that this protease can also act in a paracrine manner, stimulating fibroblast growth and invasion. 142 Data from the literature about the prognostic value of cathepsin D expression are controversial. It is not clear if the positivity of stromal cells, cancer cells or both must be evaluated and compared with clinical follow-up. Some researchers demonstrated that positivity of the cancer cells was correlated with the histologic type of mammary tumors 143, 144 and survival of the patients, thus supporting the potential of cathepsin D positivity as a prognostic marker. 145 -150 High levels of cathepsin D indicated shorter disease free-intervals for breast cancer, as well as higher recurrence 150 and metastatic rates. 152 However, others did not confirm these observations, and suggested that detection of this protease could not be an efficient prognostic marker. 149,153 -159 When the positivity of stromal cells was evaluated, Visscher et al. 160 found a correlation between fibroblast expression and the occurrence of metastases. Tetu et al. 161 also considered stromal cell positivity an indicator for survival and metastasis.
In colorectal cancer, cathepsin D overexpression was described and correlated with advanced tumoral stages, 162 as well as with lymph node metastases. 163 Nevertheless, the majority of the investigations of cathepsin D expression levels in these neoplasms did not correlate expression with clinical stages or survival. 164, 165 The prognostic value of cathepsin D immunohistochemical expression in the prognosis of non-small cell lung carcinomas is also controversial.
Higashiyama et al. 166 did not find prognostic value for the immunostaining of cancer cells in this neoplasm, but did for stromal cells. Mimae et al. 167 identified that higher expression of cathepsin D correlated with worse prognosis in patients with pulmonary adenocarcinoma.
Since the discovery of cysteine-cathepsins, which are promoters of the metastatic potential in cancer cells, 168 several studies have investigated the role of these proteases in cancer progression. 169 Currently, cysteine cathepsins presents two pathways with apparently opposing functions in cancer progression: ECM degradation promoting tumor invasion in the extracellular space and by participating in apoptotic pathways dependent on translocation of cathepsins into the cytosol. 170 Cathepsin B is the most frequently associated with tumoral progression, followed by cathepsin L. 169 These two proteases are present in almost all mammalian cells, 171 and activate the precursors of uPA, promoting the formation of plasmin. 172 Cathepsin B, present in cells mainly in its membrane-associated form, can degrade collagen, fibronectin, laminin and proteoglycans. High levels of this protease were identified in malignant cells 173 with positive correlation between cathepsin B expression and nodal metastatic in Inflammatory breast cancer patients suggesting that this proteolytic enzyme may promote nodal metastasis. 174 Cathepsin L is responsible for cleavage of collagen, elastin and proteoglycans. Data from the literature correlate its augmented membrane-associated activity with higher metastatic rates. 175 It has been proposed that cathepsins B and L, along with other proteinases such as cathepsin D, uPA and MMPs, are subject to activation in cascade. The impaired regulation of this cascade in tumor tissues results in uncontrolled proteolysis of ECM components such as laminin, fibronectin and type IV collagen, which is one of the preconditions for local invasion and metastasis. 176 It was suggested that the immunohistochemical analysis for cathepsins B and L is not a useful tool for estimating prognosis in human breast cancer. 158, 177 However, cathepsin B was correlated with cancer progression in lung, 178 urinary bladder 179 and colorectal carcinomas, 180 and malignant melanomas. 181 In gastric carcinomas, immunostaining for cathepsins B and L was correlated with lymphatic and blood vessel invasion, respectively. 182 The quantification of these proteases using enzyme-linked immunosorbent assay (ELISA) was investigated in mammary cancer patients. It was demonstrated that higher activity and concentrations of cathepsin B were related to shorter overall survival, 151, 183 as well as recurrence and death due to the disease. 184 Cytosolic cathepsin L levels were also an independent prognostic marker. 185 Higher levels of cathepsin B and L were also observed in head and neck squamous cell carcinomas in comparison to levels in normal tissues, 186 as well as blood serum activity of these proteases. 187 Differences between cytosolic and immunohistochemical results for cathepsins B and L in mammary cancer could be explained by stromal expression of these enzymes. 176 There are scarce specific reports about the expression of cathepsin D in canine normal and tumoral tissues, or about its potential relation with histologic types, metastasis or survival. Bi et al. 188 demonstrated cathepsin D expression in cortical and thalamic neurons of young, adult and senile dogs using immunohistochemistry. Sarcomas and mast cell tumors were analyzed through quantification of cathepsins B, K, L and S levels by real-time PCR in tumoral tissue and adjacent. 189 In that work, tumoral tissue levels were higher than in the adjacent muscle tissue, in accordance with previous reports on murine sarcomas. 190 Gene expression data of canine soft tissue sarcomas also demonstrated higher expression of cathepsins in comparison to skeletal muscle. 191, 192 
Conclusion
This review highlighted the conflicting results regarding proteases expression between human and canine species, even when comparing the same neoplasms. Thus, the microenvironment of each tumor needs to be considered when trying to understand the complex nature of tumorigenesis. A better understanding of the regulation of this microenvironment and its influences in tumor progression and metastasis should significantly aid the development of improved prognosis and treatment. 
